Considering the dynamic nature of body mass index (BMI) and its importance in determining cardiovascular risks, this study aimed to investigate the life-course trajectory pattern of women's BMI and its association with cardiovascular risk factors. A total of 1356 couples with 2976 children were recruited and followed up for an average period of 20 years. Latent growth curve modeling was applied to determine women's BMI trajectories; logistic regression was used to investigate the associations between trajectory patterns and cardiovascular risk factors, including hypertension (HTN), dyslipidemia, diabetes mellitus (DM), and obesity. Women were classified into three trajectories, including normal, stage 1 obesity, and stage 2 obesity. Compared to women's in the normal trajectory group, those in obesity trajectories had higher odds ratios for HTN, DM, and dyslipidemia. Men with obese spouses showed a higher rate of HTN 1.54 (95% CI 1.05-2.25) and DM 1.55; (95% CI 1.00-2.44). The odds of men's obesity were higher in obese spouses (OR 1.70; 95% CI 1.10-2.62). Offspring of stage 2 obese (OR 2.39; 95% CI 1.67-3.44) and stage 1 obese (OR 4.81; 95% CI 3.16-7.34) mothers were more likely to be obese. Our findings emphasized paying more attention to women with excessive weight to promote familial cardiovascular health in the communities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397790 | PMC |
http://dx.doi.org/10.1038/s41598-021-96154-5 | DOI Listing |
Genome Med
December 2024
European Reference Network for Rare Multisystemic Vascular Disease (VASCERN), HTAD and MSA Rare Disease, Working Group, Paris, France.
Background: In 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) developed standardized variant curation guidelines for Mendelian disorders. Although these guidelines have been widely adopted, they are not gene- or disease-specific. To mitigate classification discrepancies, the Clinical Genome Resource FBN1 variant curation expert panel (VCEP) was established in 2018 to develop adaptations to the ACMG/AMP criteria for FBN1 in association with Marfan syndrome.
View Article and Find Full Text PDFBMC Public Health
December 2024
Muhimbili University of Health and Allied Sciences, Dar es salaam, United Republic of Tanzania.
Introduction: It is estimated that 1.3 billion people in the world have hypertension and a large proportion of them are unaware. Waist circumference has emerged as Potential predictor of Cardiovascular Diseases (CVD) risk; however, fewer studies in Tanzania have evaluated its role in screening for CVD risk.
View Article and Find Full Text PDFLight Sci Appl
January 2025
Center for Nanoscience and Technology, Istituto Italiano di Tecnologia, Milano, 20134, Italy.
We introduce a family of membrane-targeted azobenzenes (MTs) with a push-pull character as a new tool for cell stimulation. These molecules are water soluble and spontaneously partition in the cell membrane. Upon light irradiation, they isomerize from trans to cis, changing the local charge distribution and thus stimulating the cell response.
View Article and Find Full Text PDFHipertens Riesgo Vasc
December 2024
Facultad de Ciencias Médicas, Universidad Nacional de La Plata, Argentina; Centro de Investigaciones Cardiovasculares "Dr. Horacio E. Cingolani" CONICET-UNLP, Argentina. Electronic address:
Background: Blood pressure (BP) is linearly related to the incidence of cardiovascular disease from values as low as 115/75mmHg, even at young ages. A particularly concerning issue is the decrease representation of optimal BP among children and youth. The mechanisms by which minimal elevations in BP increase cardiovascular risk are not defined.
View Article and Find Full Text PDFClin Investig Arterioscler
December 2024
Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Riesgo Vascular, Hospital del Mar, Barcelona, España. Electronic address:
Given the apparent inconsistency of having potent lipid-lowering drugs and the unacceptable rate of achievement of therapeutic goals in LDL cholesterol, it is imperative to define new strategies. In this regard, it is appropriate to detail the key points in planning to start lipid-lowering therapy, emphasizing relevant clinical aspects such as the considerable individual variability in the response to statin therapy, positioning in relation to high-potency statins versus statin+ezetimibe combination therapy, and the order of choice of lipid-lowering drugs in the therapeutic strategy. An algorithm is then proposed that ensures a personalized approach to lipid-lowering drug treatment in patients with cardiovascular disease and/or familial hypercholesterolemia with the aim of achieving the therapeutic goal in the shortest possible time, taking into account the patient's previous treatment, the funding criteria for new drugs, and the individualized goal of LDL cholesterol reduction.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!